Latest Heart failure Stories

Study will evaluate the second generation Barostim neo(TM) MINNEAPOLIS, April 29, 2013 /PRNewswire/ -- CVRx, Inc., a private medical device company, received Food and Drug Administration (FDA) investigational device exemption (IDE) approval, allowing the company to proceed with its hypertension study. The study is evaluating the safety and effectiveness of CVRx's Barostim neo(TM) in treating hypertension (high blood pressure). The prospective, randomized and controlled study will enroll...

MINNEAPOLIS, April 29, 2013 /PRNewswire/ -- CVRx, Inc., a private medical device company, announced the first patient enrolled in the Barostim HOPE4HF clinical trial. The study is evaluating the effectiveness and safety of CVRx's Barostim neo in heart failure patients. Dr. Richard Abben, Director of Cardiac Intervention, with the Cardiovascular Institute of the South, in Houma, Louisiana is the Principal Investigator for the center. The prospective, randomized and controlled study...

DEERFIELD, Ill., April 26, 2013 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Jack Cooper et al. v. Takeda Pharmaceuticals America, Inc., et al., No. CGC-12-518535 the jury found in favor of the plaintiffs and awarded a total of $6.5 million in damages. Takeda has filed motions asking the judge to rule in favor of the company as a matter of law and is considering its options, including a possible appeal if the motions are denied. The trial...

Brett Smith for redOrbit.com - Your Universe Online By working with mouse and fruit fly hearts, researchers at Washington University (WUSTL) School of Medicine, St. Louis identified a key protein that has a connection with Parkinson’s disease and heart failure. According to a new report in the journal Science, a protein known as mitofusin 2 (Mfn2) is the missing link in the chain-reaction that starts with mitochondrial dysfunction and ends with Parkinson’s disease or heart failure,...

Novel treatment has potential in multiple cardiovascular diseases Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation reduces blood pressure in patients who do not respond to conventional drug therapy. Use of the technique is increasing in Europe and worldwide and several national societies have published guidance...

April Flowers for redOrbit.com - Your Universe Online The American Heart Association (AHA) issued a statement this week that predicts the number of people with heart failure could rise 46 percent – from 5 million in 2012 to 8 million in 2030 – and that the direct and indirect costs to treat heart failure could more than double -- from $31 billion in 2012 to $70 billion in 2030. This means every US taxpayer could be paying $244 a year to care for heart failure patients by 2030. The...

DENVER, April 24, 2013 /PRNewswire-USNewswire/ -- Omega-3 polyunsaturated fatty acids (PUFAs), namely DHA and EPA found in fatty fish, are associated with lower risk of heart failure mortality in adults with chronic heart failure or who have experienced a heart attack. These fatty acids may also benefit young adults at risk of cardiovascular disease due to impaired fetal growth and low birth weight. These findings and more are summarized in the April 2013 PUFA Newsletter. A study of...

WALTHAM, Mass., April 23, 2013 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a leading provider of near-patient diagnostics and health information solutions, is pleased to announce the final results of the HABIT pilot study, which were recently published in the Journal of the American College of Cardiology. Led by Dr. Alan Maisel, Professor of Medicine at the University of California, San Diego, the study is the first to capture serial data from patients at high risk for recurrent acute...

Baylor College of Medicine researchers will lead a three-year, $4.2 million study funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to determine whether drugs called beta blockers can ease airway narrowing in patients with asthma and examine potential mechanisms. Researchers from Duke University in Durham, North Carolina, and Washington University in St. Louis, Missouri, also will participate. "Previously, beta...

Silicon BioDevices 'Lab-in-the-Hand' Previewed at 45th Annual Oak Ridge Conference BALTIMORE, April 18, 2012 /PRNewswire/ -- Silicon BioDevices, based in Berkeley, Calif., today presented the results of a pivotal benchmark study of its digital handheld device for high-sensitivity measure­ment of cardiac troponin-I, a protein found in the heart muscle used to identify heart tissue dam­age in patients suspected of having a heart attack. The study showed that the totally integrated,...